Adjunctive Use of Tafluprost with Timolol Provides Additive Effects for Reduction of Intraocular Pressure in Patients with Glaucoma

Abstract

As adjunctive therapy to timolol, tafluprost achieved a consistently greater reduction in IOP compared with vehicle, and was well tolerated.

Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial

“…Tafluprost, similar to other PGAs, has a favourable safety and efficacy profile . The results of this study align well with the findings of our earlier large 12‐week phase III clinical trial conducted in the USA and Europe in patients with OAG or OHT who were predominantly white (75%) or black (23%), with < 2% being Asian .…”

“…Numerous studies have analysed the safety and efficacy of tafluprost in comparison with those of placebo and other hypotensive agents . Similar reductions in IOP have been achieved with PF and PC formulations of tafluprost in subjects with glaucoma and OHT .…”

Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open‐angle glaucoma and ocular hypertension: 24‐month results of a randomized, double‐masked phase III study

“…In two phase I randomized, placebocontrolled studies in healthy volunteers, administration of tafluprost eye drops once-daily resulted in a significantly greater reduction in IOP compared with placebo, and tafluprost at a concentra-Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study tion of 0.005% was significantly more effective than latanoprost in reducing IOP (Sutton et al 2007(Sutton et al , 2008. Tafluprost has also shown an IOP-lowering effect and a good tolerability profile in several shorter term phase II ⁄ III studies in patients with glaucoma (Traverso et al 2006;Hamacher et al 2008;Egorov & Ropo 2009).…”

Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension

“…For tafluprost versus latanoprost, noninferiority was demonstrated by ANOVA (and almost by ANCOVA) in a phase III, 24-month study in patients with open-angle glaucoma or ocular hypertension 17. In addition, the IOP-lowering efficacy of tafluprost in adjunctive use with timolol demonstrated by Egorov and Ropo 18. A clinical equivalence between preservativefree and preservative-containing prescriptions has been reported both by Uusitalo H et al19 in healthy volunteers, and by Hamacher T et al22 in patients with glaucoma or ocular hypertension.…”